Box 5
Contains 10 Results:
Correspondence with research laboratories on testing and research on Candidin; correspondence on licensing agreements; and a confidential report on the assay procedure for Candidin.
Letters to drug companies regarding license agreements.
Correspondence on patent application and Patent Office proceedings on No. 497,548 filed March 29, 1955, but rejected on July 24, 1961.
Reports, correspondence, and memoranda regarding trademark protection in foreign countries; licensing agreements with Merck and other drug companies; Neomycin Production standards and price reduction.
Correspondence on clinical cases, experimental animal studies; several reports in French; spectrophotometer charts, data charts, news release.
Correspondence and reports with data on production and standardization.
Correspondence on Neomycin infringements.
Patent application Serial #76,184 dated February 12, 1949 and Serial #131,686 dated December 7, 1949, and correspondence regarding foreign applications, especially two oppositions lodged in Japan by Takeda and Mitsubishi.
This file concerns claims by Dr. Umezawa to have discovered Neomycin first. SAW's letter to R. Dunham November 8, 1951 explains history of his discovery and evidence submitted by Umezawa, as well as copies of journal articles translated into English from the Japanese Medical Journal submitted by Umezawa from 1948-1950. NOTE: Photocopies of letters to/from SAW of very poor quality.
Patent application No. 596,860 dated January 27, 1950; correspondence and memoranda regarding difficulties with Paromomycin, an antibiotic developed by Parke-Davis, with a chemical structure different from Neomycin in the substitution of an OH group in place of a second NH2 group.